LUF 6283HCA2 (GPR109A) partial agonist CAS# 92933-48-7 |
- HG-10-102-01
Catalog No.:BCC4271
CAS No.:1351758-81-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 92933-48-7 | SDF | Download SDF |
PubChem ID | 6485181 | Appearance | Powder |
Formula | C8H12N2O2 | M.Wt | 168.19 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | 5-butyl-1H-pyrazole-3-carboxylic acid | ||
SMILES | CCCCC1=CC(=NN1)C(=O)O | ||
Standard InChIKey | ZJTXSGLJNBAMJS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C8H12N2O2/c1-2-3-4-6-5-7(8(11)12)10-9-6/h5H,2-4H2,1H3,(H,9,10)(H,11,12) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Partial agonist of hydroxycarboxylic acid receptor 2 (HCA2) (Ki = 0.55 μM). Thought to lower plasma very-low-density lipoprotein (VLDL)-triglyceride levels by affecting hepatic VLDL production in normolipidemic C57BL/6 mice. |
LUF 6283 Dilution Calculator
LUF 6283 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.9457 mL | 29.7283 mL | 59.4566 mL | 118.9131 mL | 148.6414 mL |
5 mM | 1.1891 mL | 5.9457 mL | 11.8913 mL | 23.7826 mL | 29.7283 mL |
10 mM | 0.5946 mL | 2.9728 mL | 5.9457 mL | 11.8913 mL | 14.8641 mL |
50 mM | 0.1189 mL | 0.5946 mL | 1.1891 mL | 2.3783 mL | 2.9728 mL |
100 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.1891 mL | 1.4864 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 7-Oxo-ganoderic acid Z
Catalog No.:BCN7973
CAS No.:929248-72-6
- GSK461364
Catalog No.:BCC3788
CAS No.:929095-18-1
- Pracinostat (SB939)
Catalog No.:BCC2152
CAS No.:929016-96-6
- DB07268
Catalog No.:BCC1519
CAS No.:929007-72-7
- PF-03716556
Catalog No.:BCC2084
CAS No.:928774-43-0
- IRAK inhibitor 2
Catalog No.:BCC1655
CAS No.:928333-30-6
- AS 1892802
Catalog No.:BCC6335
CAS No.:928320-12-1
- MN 64
Catalog No.:BCC6489
CAS No.:92831-11-3
- Boc-D-Asp-OBzl
Catalog No.:BCC3370
CAS No.:92828-64-3
- 3-Chloro-1-(4-octylphenyl)-propanone
Catalog No.:BCN2249
CAS No.:928165-59-7
- Tenacissoside F
Catalog No.:BCN4472
CAS No.:928151-78-4
- Alisol O
Catalog No.:BCN3362
CAS No.:928148-51-0
- Fmoc-Tyr-OH
Catalog No.:BCC3562
CAS No.:92954-90-0
- Bavisant
Catalog No.:BCC1402
CAS No.:929622-08-2
- Bavisant dihydrochloride
Catalog No.:BCC1403
CAS No.:929622-09-3
- Sessilifoline A
Catalog No.:BCN4473
CAS No.:929637-35-4
- Cucumegastigmane I
Catalog No.:BCN4474
CAS No.:929881-46-9
- SGI-110
Catalog No.:BCC2221
CAS No.:929901-49-5
- 3,4-Dimethoxybenzyl Alcohol
Catalog No.:BCN2721
CAS No.:93-03-8
- 3,4-Dimethoxybenzoic acid
Catalog No.:BCN4475
CAS No.:93-07-2
- 2-Acetonaphthone
Catalog No.:BCC8510
CAS No.:93-08-3
- Guaifenesin
Catalog No.:BCN2977
CAS No.:93-14-1
- Methyleugenol
Catalog No.:BCN4074
CAS No.:93-15-2
- Methyl isoeugenol
Catalog No.:BCN8462
CAS No.:93-16-3
Ultrasound characteristics of experimentally induced luteinized unruptured follicles (LUF) and naturally occurring hemorrhagic anovulatory follicles (HAF) in the mare.[Pubmed:21958645]
Theriogenology. 2012 Feb;77(3):514-24.
The development of hemorrhagic anovulatory follicles (HAF) involves luteinization and hemorrhage of the follicle. This is observed on ultrasound as an increase in the echogenicity of the granulosa layer and formation of echoic particles in the antrum. The inhibition of prostaglandin synthesis with flunixin meglumine (FM) during the periovulatory period induces ovulatory failure with development of luteinized unruptured follicles (LUF). These two types of anovulatory follicles appear to share similar ultrasound features but they have not been compared critically. The following endpoints: follicle diameter, follicular contents score, interval from hCG administration to beginning of follicular hemorrhage, interval from hemorrhage to organization of follicular contents, and cycle length were studied and compared in mares with HAF (n = 11) and LUF (n = 13). The objective of this study was to elucidate whether these two unruptured follicles have a consistent clinical pattern of development and therefore can be considered as part of the same anovulatory syndrome. None of the endpoints analyzed differed significantly between HAF and LUF. However, there was a greater individual variation in HAF as compared with LUF in regards to interval from hCG to hemorrhage, follicular diameter at the administration of hCG, and beginning of hemorrhage. In conclusion, HAF share a similar cascade of ultrasound characteristics with the experimentally induced LUF. This finding may provide new insights in elucidating the pathogenesis of HAF.
LuF[SeO3]: the structural chameleon of lanthanoid fluoride oxoselenates(IV).[Pubmed:24024560]
Inorg Chem. 2013 Oct 7;52(19):10788-94.
LuF[SeO3] is a compound that can easily be obtained by a solid-state reaction of Lu2O3, LuF3, and SeO2 with CsBr as the fluxing agent. The outstanding property of LuF[SeO3] is the appearance of two phase transitions within a range of less than 200 K. With an increase in the coordination number for Lu(3+) from 7 to 8, the triclinic room-temperature modification changes at temperatures below -40 degrees C to the monoclinic low-temperature or high-pressure phase of LuF[SeO3]. At the same time, room-temperature modification retains the structure but gains higher symmetry at the second phase transition of around +110 degrees C. This second transition can even be observed under a microscope using polarized light to see twinning lamellae disappear and reappear during this reversible process.
Solvothermal synthesis and upconversion properties of about 10 nm orthorhombic LuF(3): Yb(3)(+), Er(3)(+) rectangular nanocrystals.[Pubmed:26298284]
J Colloid Interface Sci. 2015 Dec 1;459:224-229.
The Yb(3+) and Er(3+) codoped orthorhombic LuF3 rectangular nanocrystals (NCs) with the size of about 10nm were synthesized by a facile and effective solvothermal process. X-ray diffraction (XRD), transmission electron microscopy (TEM), high-resolution transmission electron microscopy (HRTEM), upconversion (UC) luminescence spectra and decay curves were used to characterize the resulting samples. Compared with YF3 and alpha-NaYF4 NCs, owning the similar size and the same doping levels of Yb(3+) ions and Er(3+) ions as LuF3 NCs, the green UC emission of LuF3 NCs is 18.7 times and 5.1 times stronger than that of YF3 and alpha-NaYF4 NCs respectively; the red UC emission of LuF3 NCs is 13.2 times and 0.6 times stronger than that of YF3 and alpha-NaYF4 NCs respectively. Under 980 nm wavelength excitation, the decay curves of both (4)S3/2-->(4)I15/2 transition and (4)F9/2-->(4)I15/2 transition exhibit a single exponential function, resulting from the fast energy migrations among Yb(3+) ions caused by the high concentration of Yb(3+) ions (20 mol%). Meanwhile, at relatively low power density, the slopes of the linear plots between log(I) and log(P) for green UC and red UC are 1.7 and 1.9 respectively, which are less than 2 due to the quenching of the thermal effect, indicating a two-photon process for them. At high power density, the slopes are decreased caused by the saturation effect. In addition, we proved the existence of the thermal effect by the pump power dependence of the intensity ratio of (2)H11/2-->(4)I15/2 transition to (4)S3/2-->(4)I15/2 transition.
Low valency in lanthanides: a theoretical study of NdF and LuF.[Pubmed:24929395]
J Chem Phys. 2014 Jun 14;140(22):224314.
The ground and low-lying excited state potential energy curves of neodymium monofluoride were calculated using multireference (CASSCF) and single reference (EOM-CR-CCSD(T)) methods. Optimized bond lengths were obtained and accurate bond dissociation energies were computed. The EOM-CR-CCSD(T) method was used to determine the bond dissociation energy of lutetium monofluoride, and it is shown that core correlation is required to produce bond dissociation energies in agreement with experiment.